Immuneering (IMRX) Net Income towards Common Stockholders (2020 - 2023)
Historic Net Income towards Common Stockholders for Immuneering (IMRX) over the last 4 years, with Q4 2023 value amounting to -$15.5 million.
- Immuneering's Net Income towards Common Stockholders fell 1543.57% to -$15.5 million in Q4 2023 from the same period last year, while for Sep 2024 it was -$15.5 million, marking a year-over-year increase of 7051.25%. This contributed to the annual value of -$54.8 million for FY2023, which is 849.74% down from last year.
- Immuneering's Net Income towards Common Stockholders amounted to -$15.5 million in Q4 2023, which was down 1543.57% from -$13.1 million recorded in Q3 2023.
- Over the past 5 years, Immuneering's Net Income towards Common Stockholders peaked at -$3.6 million during Q2 2020, and registered a low of -$15.5 million during Q4 2023.
- For the 4-year period, Immuneering's Net Income towards Common Stockholders averaged around -$10.2 million, with its median value being -$11.5 million (2022).
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first plummeted by 12162.34% in 2021, then plummeted by 81.48% in 2023.
- Over the past 4 years, Immuneering's Net Income towards Common Stockholders (Quarter) stood at -$5.8 million in 2020, then tumbled by 88.02% to -$11.0 million in 2021, then dropped by 22.75% to -$13.5 million in 2022, then fell by 15.44% to -$15.5 million in 2023.
- Its last three reported values are -$15.5 million in Q4 2023, -$13.1 million for Q3 2023, and -$12.3 million during Q2 2023.